Avelumab - Merck

Drug Profile

Avelumab - Merck

Alternative Names: Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer AIO Studien gGmbH; Dana-Farber Cancer Institute; Debiopharm; Effector Therapeutics; EMD Serono; Fred Hutchinson Cancer Research Center; Hospices Civils de Lyon; Merck KGaA; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; University of Birmingham; University of California, San Diego; Vaccinex; Vanderbilt-Ingram Cancer Center; Verastem
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma
  • Registered Urogenital cancer
  • Phase III Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Liposarcoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase II Endometrial cancer; Gestational trophoblastic disease; Glioblastoma; Intestinal cancer; Nasopharyngeal cancer; Osteosarcoma; Peripheral T-cell lymphoma; Recurrent respiratory papillomatosis; Solid tumours; Thymoma
  • Phase I/II Fallopian tube cancer; Leiomyosarcoma; Peritoneal cancer
  • Phase I Hepatocellular carcinoma; Hodgkin's disease

Most Recent Events

  • 04 Dec 2017 Johannes Gutenberg University Mainz and Merck plans a phase II trial for Neuroendocrine-carcinoma (Second-line therapy or greater; Late-stage disease; Metastatic disease) in Germany (NCT03352934)
  • 27 Nov 2017 The National Institute for Health and Care Excellence invites Merck to submit a Cancer Drugs Fund proposal for avelumab for Merkel cell carcinoma
  • 14 Nov 2017 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top